{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T14:39:48Z","timestamp":1759588788163},"reference-count":42,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2006,7,19]],"date-time":"2006-07-19T00:00:00Z","timestamp":1153267200000},"content-version":"vor","delay-in-days":4217,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Prostate"],"published-print":{"date-parts":[[1995,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The effects of estrogens and progestogens in the management of prostatic adenocarcinoma are generally believed to be related to their suppressive effect on the hypothalamic\u2010pituitary\u2010testicular axis, but other mechanisms have also been suggested. The present study was designed to investigate if an androgen\u2010insensitive human prostatic cancer cell line (PC\u20103) is sensitive to estrogens or progestogens and to elucidate possible mechanisms of action. Both estrogens and progestogens in high doses (10<jats:sup>\u22125<\/jats:sup> M) suppressed tumor cell growth. At these high doses medroxyprogesterone acetate (MPA) most effectively reduced the uptake of <jats:sup>86<\/jats:sup>rubidium chloride, indicating the strongest effect on ion transport and membrane permeability. Effects on rubidium transport were also seen after estrogen treatment. It is suggested that estrogens and progestogens have direct cytotoxic effects on prostatic carcinoma cells in vitro, possibly by an effect on the cell membrane.<\/jats:p>","DOI":"10.1002\/pros.2990260103","type":"journal-article","created":{"date-parts":[[2007,2,21]],"date-time":"2007-02-21T03:22:56Z","timestamp":1172028176000},"page":"5-11","source":"Crossref","is-referenced-by-count":6,"title":["Effects of estrogens and progestogens on the membrane permeability and growth of human prostatic carcinoma cells (PC\u20103) in vitro"],"prefix":"10.1002","volume":"26","author":[{"given":"Anders","family":"Widmark","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roger","family":"Henriksson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anders","family":"Bergh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kjell","family":"Grankvist","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan\u2010Erik","family":"Damber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2006,7,19]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.1.5583.28"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00254431"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.1986.tb05461.x"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1002\/pros.2990120402"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1002\/pros.2990170107"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-11-7-663"},{"key":"e_1_2_1_8_2","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/S0022-5347(17)44996-2","article-title":"Comparison of diethylstilbestrol, cyproterone acetate and medroxyprogesterone acetate in the treatment of prostatic cancer: final analysis of a randomized phase III trial of the European organization for research on treatment of cancer urological group","volume":"136","author":"Pavone\u2010Macaluso M","year":"1986","journal-title":"J Urol"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19900815)66:4<655::AID-CNCR2820660409>3.0.CO;2-P"},{"key":"e_1_2_1_10_2","first-page":"445","article-title":"High\u2010dose medroxyprogesterone acetate (MPA) treatment of advanced prostatic carcinoma. A preliminary report","volume":"611","author":"Nilsson T","year":"1982","journal-title":"Excerpta Med Int Congr Ser"},{"key":"e_1_2_1_11_2","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1159\/000472440","article-title":"High\u2010dose medroxyprogesterone in the treatment of advanced therapy\u2010resistant prostatic carcinoma","volume":"11","author":"Johansson JE","year":"1985","journal-title":"Eur Urol"},{"key":"e_1_2_1_12_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000472441","article-title":"High\u2010dose medroxyprogesterone acetate versus prednisolone in hormone\u2010resistant prostatic cancer","volume":"11","author":"Foss\u00e5 SD","year":"1985","journal-title":"Eur Urol"},{"key":"e_1_2_1_13_2","volume-title":"Cancer of the Prostate and Kidney","author":"Denis L","year":"1983"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1080\/00365599.1988.11690377"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1210\/endo-103-5-1768"},{"key":"e_1_2_1_16_2","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1159\/000473940","article-title":"Progestogens in prostatic cancer","volume":"4","author":"Denis L","year":"1978","journal-title":"Eur Urol"},{"key":"e_1_2_1_17_2","first-page":"288","article-title":"Androgen receptors in prolactin\u2010producing pituitary tumors in rats","volume":"86","author":"Attramadal A","year":"1977","journal-title":"Acta Endocrinol (Copenh)"},{"key":"e_1_2_1_18_2","first-page":"544","article-title":"The cellular mechanism of the antiandrogenic action of normegestrol acetate, a new 19\u2010nor progestagen, on rat prostate","volume":"115","author":"Botella J","year":"1987","journal-title":"Acta Endocrinol (Copenh)"},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.ph.46.030184.000543"},{"key":"e_1_2_1_20_2","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1159\/000472774","article-title":"Effects of medroxyprogesterone acetate, alone or in combination with epirubicin hydrochloride, on the growth of the Dunning R3327H prostatic adenocarcinoma","volume":"13","author":"Landstr\u00f6m M","year":"1987","journal-title":"Eur Urol"},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.1210\/edrv-11-2-201"},{"key":"e_1_2_1_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/0303-7207(78)90083-7"},{"key":"e_1_2_1_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0074-7696(08)61959-2"},{"key":"e_1_2_1_24_2","doi-asserted-by":"publisher","DOI":"10.1210\/en.131.3.1305"},{"key":"e_1_2_1_25_2","first-page":"171","article-title":"Estrogen inhibits proliferation of the human prostatic carcinoma cell line PC\u20103","volume":"11","author":"Daehlin L","year":"1992","journal-title":"Exp Clin Endocrinol"},{"key":"e_1_2_1_26_2","first-page":"16","article-title":"Establishment and characterisation of a human prostatic carcinoma cell line (PC\u20103)","volume":"17","author":"Kaighn ME","year":"1979","journal-title":"Invest Urol"},{"key":"e_1_2_1_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/0303-7207(83)90034-5"},{"key":"e_1_2_1_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(88)90223-3"},{"key":"e_1_2_1_29_2","volume-title":"Nonparametric Statistics for Behavioral Sciences","author":"Siegel S","year":"1968"},{"key":"e_1_2_1_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)53502-8"},{"key":"e_1_2_1_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/0090-4295(93)90167-9"},{"key":"e_1_2_1_32_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.7010603"},{"key":"e_1_2_1_33_2","first-page":"303","article-title":"The effect of estramustine on microtubuli is different from the direct action via oxygen radicals on DNA and cell membrane","volume":"10","author":"Henriksson R","year":"1990","journal-title":"Anticancer Res"},{"key":"e_1_2_1_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)38615-9"},{"key":"e_1_2_1_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-12-364932-4.50010-1"},{"key":"e_1_2_1_36_2","doi-asserted-by":"publisher","DOI":"10.1002\/pros.2990190407"},{"key":"e_1_2_1_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/0022-4731(81)90043-1"},{"key":"e_1_2_1_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/0304-4157(83)90008-4"},{"key":"e_1_2_1_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/0165-7992(82)90071-9"},{"key":"e_1_2_1_40_2","volume-title":"Tumor Cell Heterogeneity. Origins and Implications","author":"Owens AH","year":"1982"},{"key":"e_1_2_1_41_2","doi-asserted-by":"publisher","DOI":"10.1002\/pros.2990050102"},{"key":"e_1_2_1_42_2","doi-asserted-by":"publisher","DOI":"10.1139\/o90-175"},{"key":"e_1_2_1_43_2","first-page":"243","article-title":"A randomized study on hormone\u2010resistant prostatic cancer: estramustine phosphate versus low dose epirubicin with or without medroxyprogesterone acetate. A Norwegian multicenter study","volume":"24","author":"Tveter KJ","year":"1990","journal-title":"Scand J Urol Nephrol"}],"container-title":["The Prostate"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpros.2990260103","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pros.2990260103","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,25]],"date-time":"2023-10-25T16:29:50Z","timestamp":1698251390000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pros.2990260103"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1995,1]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[1995,1]]}},"alternative-id":["10.1002\/pros.2990260103"],"URL":"https:\/\/doi.org\/10.1002\/pros.2990260103","archive":["Portico"],"relation":{},"ISSN":["0270-4137","1097-0045"],"issn-type":[{"value":"0270-4137","type":"print"},{"value":"1097-0045","type":"electronic"}],"subject":[],"published":{"date-parts":[[1995,1]]}}}